{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:19:45Z","timestamp":1791217185424,"version":"4.1.0"},"reference-count":149,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Providence Portland Medical Foundation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["OncoImmunology"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/2162402x.2025.2452654","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:44:36Z","timestamp":1736919876000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy"],"prefix":"10.1080","volume":"14","author":[{"given":"Kengo","family":"Tanigawa","sequence":"first","affiliation":[{"name":"Providence Cancer Institute, Portland","place":["USA"]},{"name":"Kagoshima University","place":["Kagoshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-1731","authenticated-orcid":false,"given":"William L.","family":"Redmond","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Portland","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.01.004"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028449"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028332"},{"key":"e_1_3_4_7_1","unstructured":"National Institutes of Health National Cancer Institute. Clinical trials using recombinant human interleukin-15. Bethesda (MD); [accessed 2024 Sep 19]. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials\/intervention\/recombinant-human-interleukin-15."},{"issue":"1","key":"e_1_3_4_8_1","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher RI","year":"2000","unstructured":"Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(1):S55\u20137.","journal-title":"Cancer J Sci Am"},{"issue":"1","key":"e_1_3_4_9_1","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins MB","year":"2000","unstructured":"Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1(1):S11\u20134.","journal-title":"Cancer J Sci Am"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-13"},{"key":"e_1_3_4_11_1","unstructured":"National Institutes of Health National Cancer Institute. Clinical trials using recombinant interleukin-2. Bethesda (MD); [accessed 2024 Sep 25]. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials\/intervention\/recombinant-interleukin-2."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425485"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212391"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090616"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo5409"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.5.1509"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/369333a0"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.2077"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.017"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.08.004"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034467"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00367-9"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.02.001"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041982"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1263"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1264"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01179-1"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/db20-0186"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001581"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800097"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.028"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80702-3"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000612"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2030"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1656"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00292-9"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C600321200"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1995"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.02.009"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1585"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301138111"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.012"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1175870"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6377"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062381"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.010"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.1.242"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.04.010"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni802"},{"key":"e_1_3_4_55_1","first-page":"4988","article-title":"Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism","volume":"55","author":"Gamero AM","year":"1995","unstructured":"Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 1995;55:4988\u20134994.","journal-title":"Cancer Res"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.04.010"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3183"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.661"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6830"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116161"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0567-3"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386482"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46266"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07352-w"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07254-x"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.2307\/3578216"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7516"},{"issue":"2","key":"e_1_3_4_73_1","first-page":"283","article-title":"Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma","volume":"4","author":"Redman BG","year":"1998","unstructured":"Redman BG, Hillman GG, Flaherty L, Forman J, Dezso B, Haas GP. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Clin Cancer Res. 1998;4(2):283\u2013286.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778459"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2293"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000464"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003649"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000773"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3957"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587493"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7661"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.122"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0307-5"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-169"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02307-x"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1879"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1605-0"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300736"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02104"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1379"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1520"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba5464"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1631"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00675"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004419"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00172"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02082"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104539"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00641-7"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004218"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24987-9"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-3258"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz253.051"},{"key":"e_1_3_4_112_1","first-page":"A511","article-title":"481\u2005Phase 1\/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors","volume":"9","author":"Falchook G","year":"2021","unstructured":"Falchook G, Gan H, Fu S, McKean M, Azad A, Sommerhalder D, Wang J, Tan T, Chee C, Barve M, Lemeque C, Acuff N, Pham H, Mooney J, Wang R, Marina N, Abbadessa G, Meniawy T. 481\u2005Phase 1\/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors. J For Immunother Of Cancer. 2021;9:A511.","journal-title":"J For Immunother Of Cancer"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-4518"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0304"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1744"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004991"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2173"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2601"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003155"},{"key":"e_1_3_4_121_1","unstructured":"MEDICENNA INVESTOR RELATIONS news release medicenna to present evidence of durable single agent activity and potent immune effector response with MDNA11 in the dose escalation portion of phase 1\/2 ABILITY-1 study at the 10th annual oncology innovation forum. Toronto (ON) [accessed 2024 Aug 31]. https:\/\/ir.medicenna.com\/news-releases\/news-release-details\/medicenna-present-evidence-durable-single-agent-activity-and."},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.2500"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3354"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6004"},{"key":"e_1_3_4_126_1","first-page":"A751","article-title":"718\u2005Preliminary results of GII-101-P101 (keynote-B59): GI-101 (CD80-IgG4 fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and\/or metastatic solid tumors","volume":"10","author":"Cho BC","year":"2022","unstructured":"Cho BC, Shin S, Lee JL, Shim B, Lee H, Yun N, et al. 718\u2005Preliminary results of GII-101-P101 (keynote-B59): GI-101 (CD80-IgG4 fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and\/or metastatic solid tumors. J For Immunother Of Cancer. 2022;10:A751.","journal-title":"J For Immunother Of Cancer"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.001"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05192-0"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3567"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2677"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.540"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20220-1"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007784"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008001"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2527"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.053"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12705"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2595"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0831"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT133"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2623"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3874"},{"key":"e_1_3_4_144_1","first-page":"A695","article-title":"611\u2005XTX202\u201301\/02\u2013001, phase 1\/2 first-in human study of XTX202, a masked, tumor-activated IL-2\u03b2\u03b3, in patients with advanced solid tumors: results from phase 1","volume":"11","author":"Hanna D","year":"2023","unstructured":"Hanna D, Zakharia Y, Goel S, Hurley R, Pelster M, El-Khoueiry A, et al. 611\u2005XTX202\u201301\/02\u2013001, phase 1\/2 first-in human study of XTX202, a masked, tumor-activated IL-2\u03b2\u03b3, in patients with advanced solid tumors: results from phase 1. J For Immunother Of Cancer. 2023;11:A695.","journal-title":"J For Immunother Of Cancer"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT259"},{"key":"e_1_3_4_146_1","first-page":"A830","article-title":"737\u2005737\u2005A phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors","volume":"11","author":"Moser JC","year":"2023","unstructured":"Moser JC, Opyrchal M, Rivera IR, Bilen MA, Curti B, Puzanov I, et al. 737\u2005737\u2005A phase 1\/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors. J For Immunother Of Cancer. 2023;11:A830.","journal-title":"J For Immunother Of Cancer"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT183"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05257-0"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00612-0"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.11.008"}],"container-title":["OncoImmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/2162402X.2025.2452654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T22:11:09Z","timestamp":1766095869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2025.2452654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/2162402X.2025.2452654"],"URL":"https:\/\/doi.org\/10.1080\/2162402x.2025.2452654","relation":{},"ISSN":["2162-402X"],"issn-type":[{"value":"2162-402X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2452654"}}